References
- Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010;36 (Suppl 3):S62–6.
- De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: A new therapeutic target. Cancer Treat Rev 2010;36(Suppl 3):S11–5.
- Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: Analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994;30:765–73.
- Horgan N, Shields CL, Mashayekhi A, Shields JA. Classification and treatment of radiation maculopathy. Curr Opin Ophthalmol 2010;21:233–8.
- Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007;22:151–3.
- Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416(6878):279–80.
- Sabet-Peyman EJ, Heussen FM, Thorne JE, Casparis H, Patel SJ, Do DV. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 2009;40:316–8.
- Witzel ID, Muller V, Harps E, Janicke F, Dewit M. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008;19:191–2.
- eHealthme-real world drug outcomes (internet database). Herceptin reports. Available on http://www.ehealthme.com/.